A Phase 2 interventional study of LOXO-305 in Leukemia, Lymphoid, Lymphoma, Non-Hodgkin and Lymphoma, Mantle-Cell, sponsored by Eli Lilly and Company. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 12th largest by enrollment, is one of 4 that started in 2021, is one of 11 in phase 2, and was the 3rd registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Nurix Therapeutics, Inc. · Sites in United States
Ages 18+
Jennifer Woyach · Sites in United States
Ages 75+
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 18–100
Eli Lilly and Company · Sites in United States, Australia, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 13 · Phase 3 6 · Phase 4 3
First in 2019; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 87 across the 23 interventional studies. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company: 5 open now, 9 under way, 4 of them phase 3. Of 3 finished, 1 (33%) have results posted.
Among the 13 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Eli Lilly and Company, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2021, is one of 3 in phase 2, and was the 3rd registered.
Eli Lilly and Company’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2019.
3 of the studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05254743Phase 3Loxo Oncology, Inc.A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | 2027-10 |
| NCT06466122Kerry RogersPirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi | 2026-12-31 |
| NCT06333262Inhye AhnFixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Among Eli Lilly and Company’s 13 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
This study's enrollment of 87 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Lymphoid. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with confirmed B-cell including:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 200 mg of LOXO-305 administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity.
Drug: LOXO-305
Administered orally.
Also known as: LY3527727, Pirtobrutinib
Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee
ORR was assessed by an Independent Review Committee (IRC). It was estimated based on the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). Two-sided 95% CI was calculated using the exact binomial distribution. PAS consisted of participants with Central histologically confirmed non-blastoid MCL, with no CNS metastases and treated with prior chemoimmunotherapy and BTK inhibitor-containing regimen, measurable disease at baseline as assessed using Lugano criteria, and have received at least 1 dose of study drug.
Time frame: Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)
PAS ORR: ORR Assessed by Investigator
ORR was assessed by the Investigator. It was estimated based on the percentage of participants with BOR of CR or PR. Two-sided 95% CI was calculated using the exact binomial distribution.
Time frame: Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)
PAS Best Overall Response (BOR): Percentage of Participants With CR, PR, Stable Disease (SD), Progressive Disease (PD) or Not Evaluable (NE)
BOR was assessed by the IRC and Investigator. Best overall assessment categories include (in descending order of extent of response): CR, PR, SD, PD, and NE. Two-sided 95% CI was calculated using the exact binomial distribution.
Time frame: Date of First Dose to Date of Disease Progression or Subsequent Anti-cancer Therapy (up to 100 Weeks)
PAS: Duration of Response (DOR)
DOR was assessed by the Investigator and IRC. DOR is defined as the number of months from the date of the first documented response to the date of PD or death, whichever occurs earlier. Participants who are alive and without documented PD as of data analysis cutoff date will be censored.
Time frame: Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Up to 100 Weeks)
PAS: Progression Free Survival (PFS)
PFS was assessed by the IRC and Investigator. PFS is defined as the number of months from the date of the first dose of study drug to the earlier of documented PD or death due to any cause. Participants who are alive and without documented PD as of data analysis cutoff date were censored.
Time frame: Date of First Dose to Progressive Disease or Death from Any Cause (Up to 100 weeks)
PAS: Overall Survival (OS)
OS is defined as the number of months elapsed between the date of the first dose of study drug and the date of death from any cause. Participants who are alive or lost to follow-up as of the data cutoff date will be censored.
Time frame: Date of First Dose to Date of Death from Any Cause (Up to 100 weeks)
Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve From Time Zero to Last Quantifiable Concentration(AUC[0-tlast] of LOXO-305
PK: AUC\[0-tlast\] of LOXO-305
Time frame: Cycle 1 Day 1: Predose, 1, 2, 4, 8, 12, 24 hours(h) postdose; Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 2 Day 1: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 4 Day 1: Predose, 1, 2, 4, 8 h postdose.
PK: Maximum Concentration (Cmax) of LOXO-305
PK: Cmax of LOXO-305
Time frame: Cycle 1 Day 1: Predose, 1, 2, 4, 8, 12, 24 hours(h) postdose; Cycle 1 Day 8: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 2 Day 1: Predose, 1, 2, 4, 8, 24 h postdose; Cycle 4 Day 1: Predose, 1, 2, 4, 8 h postdose.
PAS: Change From Baseline in Disease-Related Symptoms and Health-Related Quality of Life (HRQoL) Measured by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms.
Time frame: Baseline, 7 Days After Treatment Discontinuation (Up To 100 Weeks)
| Milestone | Mantle Cell Lymphoma (MCL) Cohort | Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Cohort | Other Cohort |
|---|---|---|---|
| Started | 39 | 17 | 31 |
| Received at least one dose of study drug | 39 | 17 | 31 |
| Completed | 18 | 3 | 17 |
| Not completed | 21 | 14 | 14 |
| Withdrew: Ongoing treatment | 12 | 5 | 3 |
| Withdrew: On post-treatment follow-up | 8 | 9 | 10 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
ORR was assessed by an Independent Review Committee (IRC). It was estimated based on the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). Two-sided 95% CI was calculated using the exact binomial distribution. PAS consisted of participants with Central histologically confirmed non-blastoid MCL, with no CNS metastases and treated with prior chemoimmunotherapy and BTK inhibitor-containing regimen, measurable disease at baseline as assessed using Lugano criteria, and have received at least 1 dose of study drug.
| Percentage of participants | PAS - MCL Group |
|---|---|
| Primary Analysis Set (PAS): Overall Response Rate (ORR) Assessed by Independent Review Committee | 71.4 (51.3 to 86.8) |
ORR was assessed by the Investigator. It was estimated based on the percentage of participants with BOR of CR or PR. Two-sided 95% CI was calculated using the exact binomial distribution.
| Percentage of participants | PAS - MCL Group |
|---|---|
| PAS ORR: ORR Assessed by Investigator | 64.3 (44.1 to 81.4) |
BOR was assessed by the IRC and Investigator. Best overall assessment categories include (in descending order of extent of response): CR, PR, SD, PD, and NE. Two-sided 95% CI was calculated using the exact binomial distribution.
| Percentage of participants | PAS - MCL Group |
|---|---|
| CR by IRC | 14.3 (4.00 to 32.7) |
| PR by IRC | 57.1 (37.2 to 75.5) |
| SD by IRC | 7.1 (0.9 to 23.5) |
| PD by IRC | 14.3 (4.0 to 32.7) |
| NE by IRC | 7.1 (0.9 to 23.5) |
| CR by Investigator | 14.3 (4.0 to 32.7) |
| PR by Investigator | 50.0 (30.7 to 69.4) |
| SD by Investigator | 10.7 (2.3 to 28.2) |
| PD by Investigator | 17.9 (6.1 to 36.9) |
| NE by Investigator | 7.1 (0.9 to 23.5) |
DOR was assessed by the Investigator and IRC. DOR is defined as the number of months from the date of the first documented response to the date of PD or death, whichever occurs earlier. Participants who are alive and without documented PD as of data analysis cutoff date will be censored.
| Months | PAS - MCL Group |
|---|---|
| IRC Assessment | NA (4.83 to NA) |
| Investigator Assessment | 11.50 (3.68 to NA) |
PFS was assessed by the IRC and Investigator. PFS is defined as the number of months from the date of the first dose of study drug to the earlier of documented PD or death due to any cause. Participants who are alive and without documented PD as of data analysis cutoff date were censored.
| Months | PAS - MCL Group |
|---|---|
| IRC Assessment | 9.43 (5.32 to NA) |
| Investigator Assessment | 6.80 (3.61 to 13.34) |
OS is defined as the number of months elapsed between the date of the first dose of study drug and the date of death from any cause. Participants who are alive or lost to follow-up as of the data cutoff date will be censored.
| Months | PAS - MCL Group |
|---|---|
| PAS: Overall Survival (OS) | 15.47 (8.67 to NA) |
PK: AUC\[0-tlast\] of LOXO-305
| nanogram hour per milliliter (ng*h/mL) | 200 mg LOXO-305 QD |
|---|---|
| Cycle 1 Day 1 | 62700 ± 15.0 |
| Cycle 1 Day 8 | 123000 ± 38.1 |
| Cycle 2 Day 1 | 137000 ± 28.7 |
| Cycle 4 Day 1 | 46600 ± 20.0 |
PK: Cmax of LOXO-305
| nanograms per milliliter (ng/mL) | 200 mg LOXO-305 QD |
|---|---|
| Cycle 1 Day 1 | 4800 ± 14.7 |
| Cycle 1 Day 8 | 8380 ± 35.3 |
| Cycle 2 Day 1 | 9080 ± 22.3 |
| Cycle 4 Day 1 | 7890 ± 22.5 |
EORTC QLQ-C30 v3.0 was a self-administered questionnaire with multidimensional scales that measures global health status, 5 functional domains (physical, role, cognitive, emotional, and social) and symptom scales of fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties. A linear transformation is applied to standardize the raw scores to range between 0 and 100 per developer guidelines. For functional domains and global health status, scores range from 0 to 100 with higher scores representing a better level of functioning. For symptoms scales, scores range from 0 to 100 with higher scores representing a greater degree of symptoms.
| score on a scale | PAS - MCL Group |
|---|---|
| Global health status | 2.5 ± 4.78 |
| Functional scale: Physical functioning | 0.8 ± 2.96 |
| Functional scale: Role functioning | -2.9 ± 3.57 |
| Functional scale: Emotional functioning | -2.0 ± 1.68 |
| Functional scale: Cognitive functioning | -1.0 ± 1.73 |
| Functional scale: Social functioning | -7.8 ± 3.81 |
| Symptom scale: Fatigue | -1.3 ± 3.80 |
| Symptom scale: Nausea and vomiting | 0.0 ± 1.43 |
| Symptom scale: Pain | -3.9 ± 2.27 |
| Symptom scale: Dyspnea | -2.0 ± 1.96 |
| Symptom scale: Insomnia | 2.0 ± 3.47 |
| Symptom scale: Appetite loss | -2.0 ± 4.49 |
| Symptom scale: Constipation | -3.9 ± 2.68 |
| Symptom scale: Diarrhea | 0.0 ± 0.00 |
| Symptom scale: Financial difficulties | 3.9 ± 4.85 |
Collected over Baseline Up To 100 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg LOXO-305 QD | 37/87 (42.5%) | 33/87 (37.9%) | 81/87 (93.1%) |
| Event | 200 mg LOXO-305 QD |
|---|---|
| PneumoniaInfections and infestations | 4/87 |
| Covid-19Infections and infestations | 3/87 |
| DeathGeneral disorders | 2/87 |
| BronchitisInfections and infestations | 2/87 |
| Covid-19 pneumoniaInfections and infestations | 2/87 |
| MyelosuppressionBlood and lymphatic system disorders | 1/87 |
| NeutropeniaBlood and lymphatic system disorders | 1/87 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/87 |
| Acute myocardial infarctionCardiac disorders | 1/87 |
| Ventricular extrasystolesCardiac disorders | 1/87 |
| Event | 200 mg LOXO-305 QD |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 27/87 |
| Neutrophil count decreasedInvestigations | 26/87 |
| Blood bilirubin increasedInvestigations | 20/87 |
| HypokalaemiaMetabolism and nutrition disorders | 20/87 |
| White blood cell count decreasedInvestigations | 19/87 |
| HyperuricaemiaMetabolism and nutrition disorders | 17/87 |
| Covid-19Infections and infestations | 14/87 |
| Aspartate aminotransferase increasedInvestigations | 14/87 |
| HyperglycaemiaMetabolism and nutrition disorders | 14/87 |
| PyrexiaGeneral disorders | 13/87 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | MCL Cohort | CLL/SLL Cohort | Other Cohort | Total |
|---|---|---|---|---|
| Mean | 64.1 ± 7.4 | 60.8 ± 9.2 | 59.9 ± 9.9 | 62.0 ± 8.8 |
| Sex: Female, Male(Participants) | MCL Cohort | CLL/SLL Cohort | Other Cohort | Total |
|---|---|---|---|---|
| Female | 12 | 6 | 13 | 31 |
| Male | 27 | 11 | 18 | 56 |
| Ethnicity (NIH/OMB)(Participants) | MCL Cohort | CLL/SLL Cohort | Other Cohort | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 39 | 17 | 31 | 87 |
| Race (NIH/OMB)(Participants) | MCL Cohort | CLL/SLL Cohort | Other Cohort | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 39 | 17 | 31 | 87 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | MCL Cohort | CLL/SLL Cohort | Other Cohort | Total |
|---|---|---|---|---|
| China | 39 | 17 | 31 | 87 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting
Access criteria: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting
Data sharing details ↗ · vivli.org
Ran from May 2021 to primary completion in Apr 2023, 22 months.
Results were first posted in Jul 2024, 1 year 3 months after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 22 months is below that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib
Leukemia, Lymphocytic, Chronic, B-Cell →